Esperance: Harmonizing hormones to cancer

Based on a technology invented at Louisiana State University as a means of sterilizing animals, Esperance Pharmaceuticals Inc. is developing fusion proteins that combine a tumor-seeking hormone receptor ligand and a cytotoxin to treat cancer. Next quarter, the company plans to start a Phase I trial of EP-100, which incorporates a cytotoxic peptide that may avoid resistance mechanisms because it causes tumor cell death without needing to be internalized.

"The

Read the full 694 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE